Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Estruch, Montserrat, Vittori, Camilla, Montesinos, Teresa Muñoz, Reckzeh, Kristian, Theilgaard-Mönch, Kim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992442/
https://www.ncbi.nlm.nih.gov/pubmed/35582388
http://dx.doi.org/10.20517/cdr.2021.76
_version_ 1784683731004424192
author Estruch, Montserrat
Vittori, Camilla
Montesinos, Teresa Muñoz
Reckzeh, Kristian
Theilgaard-Mönch, Kim
author_facet Estruch, Montserrat
Vittori, Camilla
Montesinos, Teresa Muñoz
Reckzeh, Kristian
Theilgaard-Mönch, Kim
author_sort Estruch, Montserrat
collection PubMed
description Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways.
format Online
Article
Text
id pubmed-8992442
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-89924422022-05-16 Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance Estruch, Montserrat Vittori, Camilla Montesinos, Teresa Muñoz Reckzeh, Kristian Theilgaard-Mönch, Kim Cancer Drug Resist Mini Review Resistance of cancer patients to DNA damaging radiation therapy and chemotherapy remains a major problem in the clinic. The current review discusses the molecular mechanisms of therapy resistance in acute myeloid leukemia (AML) conferred by cooperative chemotherapy-induced DNA damage response (DDR) and mutational activation of PI3K/AKT signaling. In addition, strategies to overcome resistance are discussed, with particular focus on studies underpinning the vast potential of therapies combining standard chemotherapy AML regimens with small molecule inhibitors targeting key regulatory hubs at the interface of DDR and oncogenic signaling pathways. OAE Publishing Inc. 2021-11-10 /pmc/articles/PMC8992442/ /pubmed/35582388 http://dx.doi.org/10.20517/cdr.2021.76 Text en © The Author(s) 2021. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Mini Review
Estruch, Montserrat
Vittori, Camilla
Montesinos, Teresa Muñoz
Reckzeh, Kristian
Theilgaard-Mönch, Kim
Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title_full Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title_fullStr Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title_full_unstemmed Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title_short Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
title_sort targeting of pi3k/akt signaling and dna damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992442/
https://www.ncbi.nlm.nih.gov/pubmed/35582388
http://dx.doi.org/10.20517/cdr.2021.76
work_keys_str_mv AT estruchmontserrat targetingofpi3kaktsignalinganddnadamageresponseinacutemyeloidleukemiaanoveltherapeuticstrategytoboostchemotherapyresponseandovercomeresistance
AT vittoricamilla targetingofpi3kaktsignalinganddnadamageresponseinacutemyeloidleukemiaanoveltherapeuticstrategytoboostchemotherapyresponseandovercomeresistance
AT montesinosteresamunoz targetingofpi3kaktsignalinganddnadamageresponseinacutemyeloidleukemiaanoveltherapeuticstrategytoboostchemotherapyresponseandovercomeresistance
AT reckzehkristian targetingofpi3kaktsignalinganddnadamageresponseinacutemyeloidleukemiaanoveltherapeuticstrategytoboostchemotherapyresponseandovercomeresistance
AT theilgaardmonchkim targetingofpi3kaktsignalinganddnadamageresponseinacutemyeloidleukemiaanoveltherapeuticstrategytoboostchemotherapyresponseandovercomeresistance

Ejemplares similares